Syndrome of inappropriate antidiuretic hormone secretion: A story of duloxetine-induced hyponatraemia

Adae Opoku Amoako, Carina Brown, Timothy Riley

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Hyponatraemia is the most commonly encountered electrolyte abnormality in clinical practice. Syndrome of inappropriate antidiuretic hormone secretion (SIADH) accounts for nearly 60% of all hyponatraemias. Selective serotonin reuptake inhibitors (SSRIs) are well known to have side effects of SIADH. There have been few reported cases of serotonin norepinephrine reuptake inhibitors (SNRIs) causing SIADH-induced hyponatraemia. Duloxetine is one type of SNRI used to treat several conditions, including depression and diabetic neuropathy. We present a case of a 76-year-old woman with a history of fibromyalgia who had recently been prescribed duloxetine for her condition. On admission to the hospital, her sodium decreased to a low of 118 mmol/L. Evaluation for other causes of hyponatraemia yielded negative results. Duloxetine was discontinued and after 3 days the patient's sodium increased to 130 mmol/L. The purpose of this case report is to highlight the importance of having suspicion for rare but real side effects of medications such as duloxetine.

Original languageEnglish (US)
Article number208037
JournalBMJ case reports
Volume2015
DOIs
StatePublished - Apr 24 2015

Fingerprint

Inappropriate ADH Syndrome
Hyponatremia
Sodium
Fibromyalgia
Diabetic Neuropathies
Serotonin Uptake Inhibitors
Electrolytes
Duloxetine Hydrochloride
Serotonin and Noradrenaline Reuptake Inhibitors

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{2bf5f61fd163437e916cc75807cf0ae1,
title = "Syndrome of inappropriate antidiuretic hormone secretion: A story of duloxetine-induced hyponatraemia",
abstract = "Hyponatraemia is the most commonly encountered electrolyte abnormality in clinical practice. Syndrome of inappropriate antidiuretic hormone secretion (SIADH) accounts for nearly 60{\%} of all hyponatraemias. Selective serotonin reuptake inhibitors (SSRIs) are well known to have side effects of SIADH. There have been few reported cases of serotonin norepinephrine reuptake inhibitors (SNRIs) causing SIADH-induced hyponatraemia. Duloxetine is one type of SNRI used to treat several conditions, including depression and diabetic neuropathy. We present a case of a 76-year-old woman with a history of fibromyalgia who had recently been prescribed duloxetine for her condition. On admission to the hospital, her sodium decreased to a low of 118 mmol/L. Evaluation for other causes of hyponatraemia yielded negative results. Duloxetine was discontinued and after 3 days the patient's sodium increased to 130 mmol/L. The purpose of this case report is to highlight the importance of having suspicion for rare but real side effects of medications such as duloxetine.",
author = "Amoako, {Adae Opoku} and Carina Brown and Timothy Riley",
year = "2015",
month = "4",
day = "24",
doi = "10.1136/bcr-2014-208037",
language = "English (US)",
volume = "2015",
journal = "BMJ Case Reports",
issn = "1757-790X",
publisher = "BMJ Publishing Group",

}

Syndrome of inappropriate antidiuretic hormone secretion : A story of duloxetine-induced hyponatraemia. / Amoako, Adae Opoku; Brown, Carina; Riley, Timothy.

In: BMJ case reports, Vol. 2015, 208037, 24.04.2015.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Syndrome of inappropriate antidiuretic hormone secretion

T2 - A story of duloxetine-induced hyponatraemia

AU - Amoako, Adae Opoku

AU - Brown, Carina

AU - Riley, Timothy

PY - 2015/4/24

Y1 - 2015/4/24

N2 - Hyponatraemia is the most commonly encountered electrolyte abnormality in clinical practice. Syndrome of inappropriate antidiuretic hormone secretion (SIADH) accounts for nearly 60% of all hyponatraemias. Selective serotonin reuptake inhibitors (SSRIs) are well known to have side effects of SIADH. There have been few reported cases of serotonin norepinephrine reuptake inhibitors (SNRIs) causing SIADH-induced hyponatraemia. Duloxetine is one type of SNRI used to treat several conditions, including depression and diabetic neuropathy. We present a case of a 76-year-old woman with a history of fibromyalgia who had recently been prescribed duloxetine for her condition. On admission to the hospital, her sodium decreased to a low of 118 mmol/L. Evaluation for other causes of hyponatraemia yielded negative results. Duloxetine was discontinued and after 3 days the patient's sodium increased to 130 mmol/L. The purpose of this case report is to highlight the importance of having suspicion for rare but real side effects of medications such as duloxetine.

AB - Hyponatraemia is the most commonly encountered electrolyte abnormality in clinical practice. Syndrome of inappropriate antidiuretic hormone secretion (SIADH) accounts for nearly 60% of all hyponatraemias. Selective serotonin reuptake inhibitors (SSRIs) are well known to have side effects of SIADH. There have been few reported cases of serotonin norepinephrine reuptake inhibitors (SNRIs) causing SIADH-induced hyponatraemia. Duloxetine is one type of SNRI used to treat several conditions, including depression and diabetic neuropathy. We present a case of a 76-year-old woman with a history of fibromyalgia who had recently been prescribed duloxetine for her condition. On admission to the hospital, her sodium decreased to a low of 118 mmol/L. Evaluation for other causes of hyponatraemia yielded negative results. Duloxetine was discontinued and after 3 days the patient's sodium increased to 130 mmol/L. The purpose of this case report is to highlight the importance of having suspicion for rare but real side effects of medications such as duloxetine.

UR - http://www.scopus.com/inward/record.url?scp=84930664321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930664321&partnerID=8YFLogxK

U2 - 10.1136/bcr-2014-208037

DO - 10.1136/bcr-2014-208037

M3 - Article

C2 - 25911354

AN - SCOPUS:84930664321

VL - 2015

JO - BMJ Case Reports

JF - BMJ Case Reports

SN - 1757-790X

M1 - 208037

ER -